Please login to the form below

Not currently logged in
Email:
Password:

Dr Georg Buchner joins Silence Therapeutics

He assumes a business development role at the London-based biotech

London-based biotech Silence Therapeutics has appointed Dr Georg Buchner VP, business development.

He was formerly VP of Corporate & Business Development at Novacta Biosystems and prior to that served as business development director at Haptogen. During that time he was instrumental in the sale of the Haptogen business to Wyeth, now part of Pfizer, in 2007

At Silence Georg will work with Tony Sedgwick, who was appointed chief business officer in September, as part of the company's strategy to continue to broaden its collaborations with global pharmaceutical and biotechnology companies.

Silence's CEO Thomas Christély said: "We are pleased to welcome Dr Georg Buchner to Silence. Georg has a strong track record in business development and his experience will strengthen our growing business development team as we seek to expand our increasing list of corporate partnerships.”

10th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics